Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Status:
Active, not recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving busulfan and fludarabine
before a stem cell transplant can help control the disease better than the standard method in
patients with leukemia, lymphoma, multiple myeloma, MDS, or MPD. In this study, 2 doses of
busulfan will be given 2 weeks before a stem cell transplant followed by 4 doses of busulfan
and fludarabine during the week before the stem cell transplant, rather than the standard
method of giving 4 doses of busulfan and fludarabine only during the week before the stem
cell transplant.
The safety of this combination therapy will also be studied.
Busulfan is designed to kill cancer cells by binding to DNA (the genetic material of cells),
which may cause cancer cells to die. Busulfan is commonly used in stem cell transplants.
Fludarabine is designed to interfere with the DNA of cancer cells, which may cause the cancer
cells to die.